10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide

Synthetic peptide
Catalog # BP6310a

Specification

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide - Product Information

Primary Accession Q9UKA8

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide - Additional Information

Gene ID 11123

Other Names
Calcipressin-3, Down syndrome candidate region 1-like protein 2, Myocyte-enriched calcineurin-interacting protein 3, MCIP3, Regulator of calcineurin 3, RCAN3, DSCR1L2

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6310a was selected from the N-term region of human DSCR1L2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide - Protein Information

Name RCAN3

Synonyms DSCR1L2

Function
Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development (By similarity).

Tissue Location
Highest expression in heart, skeletal muscle kidney, liver and peripheral blood leukocytes. Lower expression in all other tissues

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide - Images

Calcipressin 3 (DSCR1L2) Antibody (N-term) Blocking peptide - Background

DSCR1L2 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A, and may play a role during central nervous system development. Highest expression occurs in heart, skeletal muscle kidney, liver and peripheral blood leukocytes.